Zynerba Pharmaceuticals, Inc. ZYNE
Set alert
1.30 +1.30 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 70.12M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.28
- Beta
- 1.19
- Short ratio
- 0.45
- Inst. own
- 12.13%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 13, 2023
- 50-d avg
- 1.21
- 200-d avg
- 0.62141
- 1y target
- 1.25
Analyst view
Consensus: hold
Hold
Price target (mean) 1.25 -3.8% downside
Now 1.30
- Target (low)
- 1.11
- Target (mean)
- 1.25
- Target (high)
- 1.40
Ratings (0m) 7 4 buy · 3 hold · 0 sell
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 4
- 2 months ago 3
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.19 | -0.22 – 0.97 | -0.20 | +195.0% | 20.00M | 0.0% | 3 |
| Next quarter | -0.22 | -0.24 – -0.20 | -0.18 | -22.2% | 0 | 0.0% | 3 |
| Current year | -0.84 | -0.88 – -0.81 | -0.82 | -2.4% | 0 | 0.0% | 2 |
| Next year | -0.57 | -1.03 – -0.18 | -0.84 | +32.1% | 15.00M | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2023 | Canaccord Genuity | Downgrade | Buy | Hold |
| Aug 14, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jun 22, 2022 | Canaccord Genuity | Maintained | — | Buy |
| Jun 30, 2020 | Needham | Downgrade | Buy | Hold |
| May 27, 2020 | Cantor Fitzgerald | Maintained | — | Overweight |
| Oct 20, 2019 | Needham | Initiated | — | Buy |
| Apr 29, 2019 | Roth Capital | Initiated | — | Buy |
| Sep 20, 2018 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 2, 2018 | Canaccord Genuity | Maintained | Buy | Buy |
| Jan 28, 2018 | Ladenburg Thalmann | Initiated | — | Buy |
| Jan 25, 2018 | Seaport Global | Initiated | — | Buy |
| Oct 1, 2017 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Sep 28, 2017 | Canaccord Genuity | Maintained | — | Buy |
| Sep 28, 2017 | Piper Sandler | Upgrade | Neutral | Overweight |
| Aug 20, 2017 | Canaccord Genuity | Maintained | — | Buy |
| Aug 14, 2017 | Oppenheimer | Downgrade | Outperform | Market Perform |
| Aug 14, 2017 | Jefferies | Downgrade | Buy | Hold |
| Aug 7, 2017 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 27, 2017 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 23, 2017 | Maxim Group | Initiated | — | Buy |
| Dec 20, 2016 | Cantor Fitzgerald | Initiated | — | Overweight |
| Oct 6, 2016 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 16, 2016 | Roth Capital | Initiated | — | Buy |
| Nov 11, 2015 | Jefferies | Maintained | — | Buy |
| Nov 11, 2015 | Oppenheimer | Maintained | — | Outperform |
| Sep 13, 2015 | Canaccord Genuity | Initiated | — | Buy |
| Aug 30, 2015 | Piper Sandler | Initiated | — | Overweight |